Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Role of Extracellular Granzyme B in Age-related Macular Degeneration in Mouse Models

EF 2020-21

Résumé
Age-related macular degeneration (AMD) is a complex disease in which aging, genetics and environment all play significant roles. AMD affects more than 6 million individuals worldwide and treatment is an expensive, multidimensional healthcare issue in Canada. Here, I am investigating a potential target, Granzyme B (GzmB), that is a serine protease that plays a role in chronic inflammation and abnormal degradation of extracellular proteins. However, its role within the eye has not been thoroughly investigated. Thus, using a mouse model for early stage AMD, which is characterized by a thickened Bruch's Membrane (BM), I will characterize the mechanism of action of GzmB as well as its role in contributing to the abnormalities associated with early AMD by using methods such as, western blotting, immunofluorescence, immunoassays and electron microscopy. I hypothesize that GzmB contributes to AMD through the cleavage of key extracellular proteins that result in changes to the blood-retina barrier and ultimately, increased inflammation and vascular permeability of the outer retina, the area most affected by pathological changes associated with AMD. Through targeting and inhibiting GzmB as proposed here, our premise is that it will suppress the changes in the BM that present as some of the earliest indication of AMD development. The studies proposed here will assess GzmB as a potential target for future development of a first-in-class anti-protease drug to 1) suppress ECM breakdown in early AMD and 2) reduce the angiogenic and proinflammatory drive in outer retina associated with wet AMD. Inhibitors for Gzmb are already in clinical trails for other disease applications, and it may be of interest to see the inhibitors application in the eye.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449318
Name
Uppal Manjosh S
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of Extracellular Granzyme B in Age-related Macular Degeneration in Mouse Models
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Amd; Granzyme B; Protease; Retina
Abstract
Age-related macular degeneration (AMD) is a complex disease in which aging, genetics and environment all play significant roles. AMD affects more than 6 million individuals worldwide and treatment is an expensive, multidimensional healthcare issue in Canada. Here, I am investigating a potential target, Granzyme B (GzmB), that is a serine protease that plays a role in chronic inflammation and abnormal degradation of extracellular proteins. However, its role within the eye has not been thoroughly investigated. Thus, using a mouse model for early stage AMD, which is characterized by a thickened Bruch's Membrane (BM), I will characterize the mechanism of action of GzmB as well as its role in contributing to the abnormalities associated with early AMD by using methods such as, western blotting, immunofluorescence, immunoassays and electron microscopy. I hypothesize that GzmB contributes to AMD through the cleavage of key extracellular proteins that result in changes to the blood-retina barrier and ultimately, increased inflammation and vascular permeability of the outer retina, the area most affected by pathological changes associated with AMD. Through targeting and inhibiting GzmB as proposed here, our premise is that it will suppress the changes in the BM that present as some of the earliest indication of AMD development. The studies proposed here will assess GzmB as a potential target for future development of a first-in-class anti-protease drug to 1) suppress ECM breakdown in early AMD and 2) reduce the angiogenic and proinflammatory drive in outer retina associated with wet AMD. Inhibitors for Gzmb are already in clinical trails for other disease applications, and it may be of interest to see the inhibitors application in the eye.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Uppal, Manjosh S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~